Revolution Medicines seeks to bolster case for its lead cancer drug Revolution Medicines on Saturday presented updated data to bolster the case for its lead cancer drug — designed to stop tumor growth by throttling back mutations in a common cell-signaling pathway. The drug, called RMC-4630, won’t shrink tumors very much on its own. The […]
Read More
Immune-stimulating drug before surgery shows promise in early-stage pancreatic cancer PHILADELPHIA–Giving early-stage pancreatic cancer patients a CD40 immune-stimulating drug helped jumpstart a T cell attack to the notoriously stubborn tumor microenvironment before surgery and other treatments, according to a new study from researchers in the Abramson Cancer Center (ACC) at the University of Pennsylvania. Changing […]
Read More
Trastuzumab Deruxtecan Sensitivity Associated With Various Levels of HER2-Expressing Gastric … Treatment with trastuzumab deruxtecan (Enhertu; DS-8201) showed promising sensitivity in patients with with HER2 moderate-, low-, and non-expressing gastric cancer, according to data from a study presented during the virtual AACR Annual Meeting 2021.1 Trastuzumab (Herceptin) and trastuzumab deruxtecan, at various concentrations, demonstrated cytostatic […]
Read More
Login – NCCN Copyright © 2021 National Comprehensive Cancer Network, All Rights Reserved. No portion of this Site or any NCCN Content may be copied, transferred, reproduced, modified, or otherwise used for any purpose without NCCN’s express written permission.See Legal Notices Section for additional notices and terms governing your use of this Site. Published at […]
Read More